Anticancer Therapies – News and Features

A second-generation melanoma vaccine improves long-term survival, particularly for men, a new study shows.

Cisplatin is effective at killing cancer and has been used for decades, but can cause toxic side effects. Researchers have now identified a protein that, when targeted, enables cisplatin-resistant cancer cells to become responsive to treatment, allowing for the use of lower doses.

Scientists at St. Jude Children’s Research Hospital discovered that removing a second protein from cancer cells already experiencing tumor suppressor loss can reverse cancer cell identity.

Soft tissue sarcomas are rare and difficult to treat. Machine-learning tools designed at Stanford Medicine uncover distinct cellular communities that correlate with prognosis, immunotherapy success.

We spoke with Dr. Bryan Oronsky, chief development officer at EpicentRx, to discover more about the promise of multipurpose drugs and the potential of EpicentRx’s nibrozetone (RRx-001) for several conditions.

A new study has concluded that there is no evidence that cannabidiol (CBD) products reduce chronic pain, suggesting that they are not value for money and even have the potential to harm health.

Scientists have developed a coin-sized chip that can directly isolate blood plasma from a tube of blood in just 30 minutes, which is more convenient and user-friendly as compared to the current gold standard, multi-step centrifugation process.

A nanoparticle-based therapy developed by UT Southwestern Medical Center scientists stimulated an immune pathway that eradicated tumors in mouse models of various cancer types.

A subtype of Fusobacterium nucleatum underlies colorectal cancer growth and could be useful in screening and treatments, reports a new study.

Researchers at the University of Zurich and the University Hospital Zurich have discovered that a specific mutation in the cancer cells of an aggressive type of blood cancer can prevent novel immunotherapies such as CAR T-cell therapy from working.